Results 231 to 240 of about 33,784 (307)

Identification of factors limiting the efficiency of transplanting extracellular electron transfer chains in <i>Escherichia coli</i>. [PDF]

Appl Environ Microbiol
Philipp L-A, Kneuer L, Mayer-Windhorst C, Jautelat S, Le NQ, Gescher J.   +5 more
europepmc   +1 more source

Pharmacokinetic profiling of imatinib in relation to CYP3A4 activity in leukaemia patients

British Journal of Clinical Pharmacology, EarlyView.
Aim Imatinib pharmacokinetics exhibit large interindividual variability because of differences in CYP3A4 activity—the main imatinib‐metabolizing enzyme. While therapeutic drug monitoring is effective, it requires steady‐state conditions and frequent sampling.
Anna Sofie Buhl Rasmussen, Mathilde Rønne Koch, Cecilie Utke Rank, Christen Lykkegaard Andersen, Allan Weimann, Maria Thastrup, Tianwu Yang, Trine Meldgaard Lund, Ib Jarle Christensen, Flemming Nielsen, Tore Bjerregaard Stage, Sara Bisgaard Jensen, Mette Klarskov Andersen, Kjeld Schmiegelow, Kim Dalhoff   +14 more
wiley   +1 more source

Spectral discrimination of pediatric SF188 and adult glioblastoma stem cells by deep learning-enhanced Raman profiling. [PDF]

Front Oncol
Wurm LM, Fischer B, Neuschmelting V, Goldbrunner R, Croner RS, Jagielski MW, Laue D, Ertel W, Hacker MC, Dybaś J, Kahlert UD.   +10 more
europepmc   +1 more source

Evaluation of a pantoprazole and 4‐desmethylpantoprazole‐sulfate metabolic ratio as a novel CYP2C19 phenotyping method

British Journal of Clinical Pharmacology, EarlyView.
Aims CYP2C19 is one of the most important pharmacogenes, and its activity is highly variable due to factors such as genetics or drug–drug interactions. Due to the lack of an appropriate endogenous CYP2C19 biomarker, surrogate methods to assess its activity are warranted.
Julian Peter Müller, Vladimir N. Belov, Sabrina Yamoune, Bob Miller, Mohammed Hasoumi, Jolanta Tupiec, Thea Laurentius, L. Cornelius Bollheimer, Julia C. Stingl, Katja S. Just   +9 more
wiley   +1 more source

Integrating electroactive microorganisms into active soil management strategies. [PDF]

Front Microbiol
Modesto LR, Baquedano I, Ramalhete EÖ, Mena S, Sharma M, Rodríguez-Núñez P, Danilov I, Nath D, Tait N, Moro IJ, Reutina U, Yücel I, Vučetić S, Prieto A, Colliaux D, Barriuso J, Guirado G, Ieropoulos IA, Munoz-Berbel X, Grahovac J, Hanappe P, Uria N, Schmidt MR, Armstrong R.   +23 more
europepmc   +1 more source

Effect of esomeprazole on the pharmacokinetics of vepdegestrant, a PROteolysis TArgeting Chimera oestrogen receptor degrader, in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Aims The aim of this study is to evaluate the effects of multiple doses of esomeprazole, a strong proton pump inhibitor and acid‐reducing agent, on the pharmacokinetics and safety of vepdegestrant, a PROteolysis TArgeting Chimera oestrogen receptor degrader.
Lana Tran, Naihan Chen, Jennifer A. Winton, Kyle T. Matschke, Smita P. Goodman, Kimberly C. Lee, Yuanyuan Zhang, Weiwei Tan   +7 more
wiley   +1 more source

Charge Injection and Interfiber Electrical Conduction in Cable Bacteria. [PDF]

ACS Appl Mater Interfaces
Tommasi C, Gerzhik A, Heinzmann S, Martinez SH, Mayer D, Meysman FJR, van der Zant HSJ.   +6 more
europepmc   +1 more source

Codeine toxicity via breast Milk: Can this occur and implications for opiate therapy in children

British Journal of Clinical Pharmacology, EarlyView.
Codeine is commonly used in combination analgesic products. The use of codeine during breastfeeding can rarely be associated with serious adverse effects related to genetic polymorphisms affecting codeine's metabolism and disposition. Clinicians treating infants of breastfeeding mothers should be aware of this rare but potentially serious complication.
Michael Rieder
wiley   +1 more source

Study of Brain Cells in Neurodegenerative Diseases: Raman Microspectroscopy and Scanning Ion-Conductance Microscopy. [PDF]

Sovrem Tekhnologii Med
Morozova KI, Parshina EY, Kazakova TA, Yusipovich AI, Slatinskaya OV, Brazhe AR, Grivennikov IA, Brazhe NA, Maksimov GV.   +8 more
europepmc   +1 more source

First‐in‐human, phase I, randomized, safety, pharmacokinetic, food‐effect and pharmacodynamic study of a tyrosine kinase 2/Janus kinase 1 inhibitor, SDC‐1801

British Journal of Clinical Pharmacology, EarlyView.
Aim The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), food‐effect (FE) and pharmacodynamics (PD) of an oral tyrosine kinase‐2 (TYK2)/Janus kinase‐1 (JAK1) inhibitor, SDC‐1801, in healthy adult participants. Methods This first‐in‐human study randomized 95 male and female participants.
Chris Brearley, Sam Francis, John Reader, Judi Proctor   +3 more
wiley   +1 more source